UCB’s U.S. Zyrtec Sales Up Two Percent At $299 Millon

First-quarter U.S. sales of UCB’s (UCBBt.BR: Quote, Profile, Research) Zyrtec anti-hayfever drug rose two percent to $299 million, Zyrtec’s U.S. distributor Pfizer (PFE.N: Quote, Profile, Research) said on Tuesday, a result at the low end of analysts’ expectations.